// App-Quantinova.ai

: Dual Targeting of PI3Kdelta and BRD4 Sensitizes Acute Lymphoblastic Leukemia to Chemotherapy

Researchers

Presenter

  • Hye Na Kim

Principal Investigators

  • Cydney Nichols

  • Enzi Ji Jiang

  • Nour Abdel-Azim

  • Ariana Coba

  • DOnald L. Durden

  • Yong-Mi Kim

Medical Centers

  • Division of Hematology, Oncology, and Blood and Marrow Transplantation, Childrens Hospital Los Angeles, Keck School of Medicine of USC, Los Angeles, CA

  • Hematology, Oncology, Blood and Marrow Transplantation,Children's Hospital Los Angeles,Los Angeles,United States

  • Children's Hospital Los Angeles, USC, Los Angeles

  • UC San Diego, San Diego, CA

  • Division of Hematology, Oncology, and Blood and Marrow Transplantation, Childrens Hospital Los Angeles, Keck School of Medicine of USC, Los Angeles, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Asparaginase

  • Vincristine

  • CXCL12

  • Idelalisib

  • DMSO

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved